c-myc amplification in ovarian cancer

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

“…A number of genetic alterations have been observed in ovarian cancer, but little is known about their prognostic role. Cmyc amplification (Baker et al, 1990;Sasano et al, 1992) or Ki-ras mutations (Yaginuma et al, 1992) are involved in a very low percentage of cases. C-erb-B2 gene amplification and/or overexpression has been demonstrated in 20-30% of ovarian malignant tumours (Kacinski et al, 1992;Fajac et al, 1995), but these alterations do not seem to be important in identifying subsets of patients with poor prognosis.…”

Large‐scale genomic analysis of ovarian carcinomas

“…These findings are exemplified by the Progenetix database (www.progenetix.net) (Baudis and Cleary, 2001), which collates CGH and karyotype information for multiple cancer types ( Figure 1a). Amplifications targeting known oncogenes such as MYC and ERBB2 (Baker et al, 1990;Slamon et al, 1989) were identified in a proportion of cases. However, despite the increase in resolution provided by this technique, the amplicons could still not be refined sufficiently to unequivocally identify many of the specific gene targets.…”

Comparative Genomic Hybridization of Microdissected Familial Ovarian Carcinoma: Two Deleted Regions on Chromosome 15q Not Previously Identified in Sporadic Ovarian Carcinoma

“…The frequency of amplification of both 8q and 3q is similar in all studies and is probably explained by the localization of specific oncogenes already known to be involved in ovarian cancer. C-myc, localized on 8q24.12-13, is an oncogene the product of which is overexpressed in up to 30% of ovarian cancers (Baker et al, 1990). Gain of 3q material is a frequent event in several types of cancer, including head and neck cancer and cervical cancer.…”